- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12:02 | Journey Medical Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 08:54 | Journey Medical GAAP EPS of -$0.18 beats by $0.06, revenue of $13.1M beats by $1.05M | 2 | Seeking Alpha | ||
| 01:12 | Journey Medical outlines Emrosi launch momentum and targets expanded payer access in 2025 | 2 | Seeking Alpha | ||
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| Mi | Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights | 31 | GlobeNewswire (Europe) | Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions... ► Artikel lesen | |
| 07.05. | Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025 | 2 | GlobeNewswire (USA) | ||
| 30.04. | Why Journey Medical Corporation (DERM) is Surging in 2025 | 1 | Insider Monkey | ||
| 03.04. | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 01.04. | Journey Medical appoints Ramsey Alloush as COO | 1 | Seeking Alpha | ||
| 01.04. | Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer | 71 | GlobeNewswire (Europe) | SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses... ► Artikel lesen | |
| 01.04. | Journey Medical appoints new COO amid growth phase | 2 | Investing.com | ||
| 26.03. | Journey Medical GAAP EPS of -$0.72 beats by $0.44, revenue of $56.13M misses by $0.59M | 4 | Seeking Alpha | ||
| 26.03. | Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights | 622 | GlobeNewswire (Europe) | FDA Approval of Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended... ► Artikel lesen | |
| 24.03. | Journey Medical Corporation Launches Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea | 3 | GlobeNewswire (USA) | ||
| 24.03. | Journey Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 19.03. | Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 | 3 | GlobeNewswire (USA) | ||
| 05.03. | FDA approves new rosacea treatment from Journey Medical | 2 | Investing.com | ||
| 04.03. | Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida | 1 | GlobeNewswire (USA) | ||
| 20.02. | Journey Medical Corporation (DERM): A Bull Case Theory | 1 | Insider Monkey | ||
| 05.02. | Journey Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 24.01. | Minot Light Capital's Largest Performance Detractor in Q4: Journey Medical (DERM) | 2 | Insider Monkey |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 20,195 | +2,58 % | Dividendenbekanntmachungen (09.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AAK AB SE0011337708 5 SEK 0,4573 EUR ADDLIFE AB SE0014401378 0,75 SEK 0,0686 EUR ALLIANZ SE DE0008404005 - 15,4 EUR ALZCHEM GROUP... ► Artikel lesen | |
| GILEAD SCIENCES | 89,61 | +1,77 % | Gilead Sciences-Aktie: Trump als Kurs-Killer | Die US-Börsen feiern zum Wochenbeginn die Deeskalation im Handelskonflikt zwischen den USA und China. Aber Pharmawerte wie die Gilead Sciences-Aktie gehören zu den Verlierern in diesem sehr positiven... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 386,65 | +2,57 % | VERTEX PHARMACEUTICALS INC / MA - 8-K, Current Report | ||
| EYEPOINT PHARMACEUTICALS | 4,997 | +1,56 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 3,820 | +7,30 % | JMP cuts Astria Therapeutics target to $25, maintains rating | ||
| ROCKET LAB USA | 22,525 | +4,26 % | Rocket Lab: Ist der Rücksetzer eine Einstiegschance? | ||
| OPKO HEALTH | 1,148 | +1,34 % | Entera Bio Ltd.: OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders | MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 97,00 | +2,65 % | ROUNDUP: Ligand Pharmaceuticals Reiterates FY25 Outlook | WASHINGTON (dpa-AFX) - While reporting financial results for the first quarter on Thursday, biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND) reiterated its adjusted earnings and... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 95,44 | -0,04 % | Major Purchase Alert: Seamus Mulligan Invests $9.99M In Jazz Pharmaceuticals Stock | ||
| ROYALTY PHARMA | 28,930 | +0,07 % | Royalty Pharma plc: Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition | Received overwhelming shareholder approval with 99.9% of votes cast in favorSimplified structure benefits shareholders through strengthened shareholder alignment, enhanced governance, significant... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 21,280 | +1,53 % | Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y | ||
| TG THERAPEUTICS | 30,190 | +1,00 % | TG THERAPEUTICS, INC. - 10-Q, Quarterly Report | ||
| CATALENT | 59,93 | 0,00 % | Prolific Machines Appoints Former Catalent Chief Scientific Officer to Board of Directors | Expert appointment further accelerates Prolific's ability to deliver impactful protein production solutions as it prepares to expand its light-controlled bioproduction offerings
Prolific Machines... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 6,400 | 0,00 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity | CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled... ► Artikel lesen | |
| TALPHERA | 0,446 | -2,20 % | Talphera, Inc.: Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update | Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025... ► Artikel lesen |
JOURNEY MEDICAL CORPORATION gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 7,190 Euro und damit +22,28 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.